These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 16373620)
1. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions. Iribarren C Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620 [No Abstract] [Full Text] [Related]
2. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Greenland P; O'Malley PG Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539 [No Abstract] [Full Text] [Related]
3. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events. Nambi V; Ballantyne CM Curr Atheroscler Rep; 2006 Sep; 8(5):374-81. PubMed ID: 16901407 [TBL] [Abstract][Full Text] [Related]
4. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. Tsimikas S; Willerson JT; Ridker PM J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C19-31. PubMed ID: 16631506 [TBL] [Abstract][Full Text] [Related]
5. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Moriarty PM; Gibson CA Am J Cardiol; 2005 May; 95(10):1246-7. PubMed ID: 15878003 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Koenig W; Twardella D; Brenner H; Rothenbacher D Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803 [TBL] [Abstract][Full Text] [Related]
7. Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease. Myerson M Mayo Clin Proc; 2007 Jul; 82(7):888; author reply 888-9. PubMed ID: 17605973 [No Abstract] [Full Text] [Related]
8. An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction. Macphee CH; Nelson JJ Eur Heart J; 2005 Jan; 26(2):107-9. PubMed ID: 15618064 [No Abstract] [Full Text] [Related]
9. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. Sudhir K J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120 [TBL] [Abstract][Full Text] [Related]
11. Lp-PLA2: an emerging biomarker of coronary heart disease. Dada N; Kim NW; Wolfert RL Expert Rev Mol Diagn; 2002 Jan; 2(1):17-22. PubMed ID: 11963798 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for "prime time". Steinberg DI; Mayer A Mayo Clin Proc; 2007 Feb; 82(2):155-7. PubMed ID: 17290719 [No Abstract] [Full Text] [Related]
14. [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]. Piñón P; Kaski JC Rev Esp Cardiol; 2006 Mar; 59(3):247-58. PubMed ID: 16712749 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. May HT; Horne BD; Anderson JL; Wolfert RL; Muhlestein JB; Renlund DG; Clarke JL; Kolek MJ; Bair TL; Pearson RR; Sudhir K; Carlquist JF Am Heart J; 2006 Nov; 152(5):997-1003. PubMed ID: 17070179 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Kardys I; Oei HH; van der Meer IM; Hofman A; Breteler MM; Witteman JC Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):631-6. PubMed ID: 16373603 [TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544 [TBL] [Abstract][Full Text] [Related]
18. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Macphee CH; Nelson J; Zalewski A Curr Opin Pharmacol; 2006 Apr; 6(2):154-61. PubMed ID: 16495153 [TBL] [Abstract][Full Text] [Related]
19. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Albert MA; Glynn RJ; Wolfert RL; Ridker PM Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658 [TBL] [Abstract][Full Text] [Related]
20. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Moutzouri E; Tsimihodimos V; Tselepis AD Curr Pharm Des; 2013; 19(21):3827-40. PubMed ID: 23286437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]